HB 2226 Pennsylvania House · 2025-2026 Regular Session

An Act amending Title 40 (Insurance) of the Pennsylvania Consolidated Statutes, providing for prescription drug cost credits in health insurance; and imposing penalties.

HB 2226 amends Pennsylvania's Unfair Trade Practices and Consumer Protection Law to explicitly prohibit pyramid schemes and similar deceptive promotional plans. The bill adds a new definition clarifying that schemes where participants pay to join and earn compensation primarily by recruiting others (rather than through product sales) are illegal, including "chain-letter plans," "pyramid clubs," and "pyramid promotional schemes." This change directly affects businesses operating such schemes and protects consumers from being misled by these fraudulent programs. The amendment specifically bans practices like requiring participants to pay for "opportunities" to recruit others, while excluding minimal initial payments of $25 or less.

Bill status in committee 1 of 4 stages cleared

Introduction

Feb 2026

Committee Review

Floor Vote

Governor

Introduced Feb 19, 2026 Last action Jun 24, 2026

Maddy AI version diff · 1 comparison

What changed between versions

Printer's No. PN2917 → Printer's No. PN3706 · 5 edits

MODERATE

The bill text was updated from an earlier draft (PN 2917) to a later version (PN 3706) that includes significant new content. The most important change is the addition of an entirely new chapter establishing rules for crediting drug manufacturer co-pay assistance toward health insurance cost-sharing, along with new definitions and enforcement penalties. Minor text updates were also made to existing sections regarding unfair competition and motor vehicle sales disclosures.

Scope change

The bill's scope expanded significantly to include a new chapter regulating how prescription drug co-pay assistance is credited toward health plan cost-sharing, which was not present in the earlier version.

REQUIREMENT

Added a new chapter requiring health insurers to credit drug manufacturer payments toward patient cost-sharing for specific prescription drugs, with exceptions for generic drugs and high-deductible plans.

Refined the definition of unfair competition to clarify that confusion must relate to the source or sponsorship of goods, and updated motor vehicle sales disclosure requirements.

DEFINITION

Introduced new legal definitions for terms like 'drug manufacturer direct support,' 'covered person,' and 'prescription drug coverage administrator' to support the new chapter.

ENFORCEMENT

Established new penalties, including fines up to $5,000 per violation and license suspension, for entities that fail to comply with the new co-pay assistance credit rules.

TECHNICAL

Updated the list of bill sponsors and committee referral dates to reflect the current legislative status.

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Amendments

Jun 24, 2026

Committee

Re-committed to Rules

lower

Jun 24, 2026

Lower · Passed

Reported as amended

lower

Feb 19, 2026

Committee

Referred to Insurance

lower

1 primary · 31 co-sponsors